Media Release

Basel, 20 June 2016

Roche launches the new cobas e 801 module, helping hospitals meet the demand for increased diagnostic testing

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its new, dedicated high-volume testing immunoassay solution, the cobas e 801 module, is now available for countries accepting the CE Mark.1

As diagnostic laboratories evolve to meet growing workloads in an increasingly challenging environment, the cobas e 801 module offers high value through its flexibility, which allows for the efficient use of existing resources such as space, infrastructure and personnel. The module is designed for maximum consolidation at a high throughput, continuous operation and, at the same time, it reduces the amount of waste generated, for more environmentally friendly testing.

“Today, laboratories need to deliver more diagnostic tests than ever before, while in many cases their resources are constrained” said Roland Diggelmann, CEO Roche Diagnostics. “The cobas e 801 module is an important part of Roche’s connected laboratory solutions that allows laboratories to test efficiently and to sustainably grow their testing capacity.”

The cobas e 801 module almost doubles the currently available immunochemistry testing capacity on the same footprint. The system only requires a low sample volume, offers an extensive assay menu and delivers fast, reliable and consistent patient results across systems. This benefits patients and healthcare professionals by providing the accurate and timely results needed to make the correct treatment decisions.

About the cobas e 801 module and immunoassay testing

The cobas e 801 module is the newest member of the cobas 8000 modular analyzer series. It offers more than 100 immunoassays, across a wide range of disease areas. Up to four cobas e 801 modules can be configured in series, delivering up to 1’200 tests per hour across up to 192 reagent positions. The cobas e 801 allows for continuous loading of reagents and consumables and has a high uptime while requiring less hands-on time. The possible turn-around times for routine and emergency samples are the lowest available on the central laboratory market, with 18 minutes for routine and 9 minutes for emergency tests, for instance with cardiac markers.2 The small sample volumes required for testing are especially beneficial for critical patients, such as neonates and oncology patients. The cobas e 801 module uses the well-established Elecsys technology. For more information visit

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry seven years in a row by the Dow Jones Sustainability Indices.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit

All trademarks used or mentioned in this release are protected by law.
1. Local product availability may vary independently from CE Mark approval.
2. Package insert data. 2014